Ausgabe 5/2022
Inhalt (31 Artikel)
ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer
Longming Liang, Hansi Chen, Ping Mao, Yuyu Li, Lijun Xu, Yujie He, Yunping Mu, Allan Z. Zhao, Sujin Zhou, Zhenggang Zhao, Fanghong Li
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer
Danping Yuan, Yong Tao, Haoyi Wang, Jiawei Wang, Yuepeng Cao, Wen Cao, Shou Pan, Zhaonan Yu
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells
Sai-Fung Chung, Suet-Ying Tam, Chi-Fai Kim, Hiu-Chi Chong, Leo Man-Yuen Lee, Yun-Chung Leung
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines
Risa Mia Swain, Lisett Contreras, Armando Varela-Ramirez, Mohammad Hossain, Umashankar Das, Carlos A. Valenzuela, Manuel L. Penichet, Jonathan R. Dimmock, Renato J Aguilera
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer
Qun Ye, Ziwei Jiang, Ying Xie, Yuanhong Xu, Yiyi Ye, Lei Ma, Lixia Pei
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel
Minoru Horiuchi, Takehiro Uemura, Tetsuya Oguri, Sanae Toda, Sayaka Yamamoto, Yuto Suzuki, Yusuke Kagawa, Kazuki Sone, Satoshi Fukuda, Yuta Mori, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Ken Maeno, Akio Niimi
Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma
Janki M. Desai, Aniruddha S. Karve, Gary A. Gudelsky, Mruniya V. Gawali, William Seibel, Larry Sallans, Biplab DasGupta, Pankaj B. Desai
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors
Sofia I. Bär, Bernhard Biersack, Rainer Schobert
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
Tinnabhop Santadkha, Wanwisa Skolpap, Remant K.C., Aysha Ansari, Cezary Kucharski, Teo Atz Dick, Hasan Uludağ
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport
Zelin Duan, Zhiyun Zhou, Feifei Lu, Yawen Zhang, Xvqin Guo, Chunshan Gui, Hongjian Zhang
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd Bauer, Byong Chul Cho, Rebecca Heist, Lyudmila Bazhenova, Theresa Werner, Sanjay Goel, Dong-Wan Kim, Douglas Adkins, Richard D. Carvajal, Ajjai Alva, Keith Eaton, Judy Wang, Yong Liu, Xiaohong Yan, Jamie Christensen, Saskia Neuteboom, Richard Chao, Shubham Pant
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
Filip Janku, Seung-Hoon Beom, Yong Wha Moon, Tae Won Kim, Young G. Shin, Dong-Seok Yim, Gun Min Kim, Hyo Song Kim, Sun Young Kim, Jae-Ho Cheong, Young Woo Lee, Barb Geiger, Sanghee Yoo, Archie Thurston, Dean Welsch, Marc S. Rudoltz, Sun Young Rha
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
Yoshito Komatsu, Tsuneo Shimokawa, Kohei Akiyoshi, Masato Karayama, Akihiko Shimomura, Yasuyuki Kawamoto, Satoshi Yuki, Yuichi Tambo, Kazuo Kasahara
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
Toshio Shimizu, Takako Eguchi Nakajima, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Shunsuke Kondo, Yu Sunakawa, Naoki Izawa, Yoshiki Horie, Silong Xiang, Siying Xu, Lan Qin, John Gong, David Liu
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
Yu Sunakawa, Keishiro Takahashi, Osamu Kawaguchi, Nobuyuki Yamamoto
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
Xiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, R. Donald Harvey, Ki Young Chung, Farhad Sedarati, Cassie Dong, Douglas V. Faller, Karthik Venkatakrishnan, Neeraj Gupta
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J. Moschos, Shahneen Sandhu, Karl D. Lewis, Ryan J. Sullivan, Igor Puzanov, Douglas B. Johnson, Haby A. Henary, Hansen Wong, Vijay V. Upreti, Georgina V. Long, Keith T. Flaherty
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
Hisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, Takeshi Tsuda, Yutaka Yamada, Satoshi Wasamoto, Takayuki Kishikawa, Ayako Shiono, Jun Shiihara, Ou Yamaguchi, Atsuto Mouri, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Koichi Minato, Hiroshi Kagamu
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
M Mego, D Svetlovska, De Angelis V, K Kalavska, P Lesko, M Makovník, J Obertova, Z Orszaghova, P Palacka, M Rečková, K Rejlekova, Sycova-Mila Z, J Mardiak, M Chovanec
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Nabil Adra, David J. Vaughn, Lawrence H. Einhorn, Nasser H. Hanna, Samuel A. Funt, Matt Rosales, Ahsan Arozullah, Darren R. Feldman
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
Tiandong Kong, Lu Chen, Xiaoli Zhao, Fangfang Duan, Hanli Zhou, Lei Wang, Danna Liu
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study
Sae Ohwada, Akiko Todaka, Hiroshi Nakase, Hiromichi Shirasu, Takeshi Kawakami, Satoshi Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
Yu Xu, Rong Guo, Miao Miao, Guangsen Zhang, Jianping Lan, Jie Jin
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
Peng Yuan, Jinhua Song, Fei Wang, Guangyu Zhu, Baoan Chen
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046
Matteo Repetto, Edoardo Crimini, Liliana Ascione, Luca Boscolo Bielo, Carmen Belli, Giuseppe Curigliano
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report
Kei Kunimasa, Naotoshi Sugimoto, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Ryu Kanzaki, Jiro Okami, Kazumi Nishino
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Juanyan Liao, Hui Guan, Min Yu, Ping Zhou, Yao Han, Xingchen Peng, Shuang Zhang
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model
Haomin Lin, Bin Luo, Fangyi Peng, Cheng Fang, Yu Gan, Xiaoli Yang, Bo Li, Yaling Li, Song Su
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome
Yang He, Weijin Fang, Zuojun Li, Chunjiang Wang
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
Xinyi Lin, Xiaojuan Yang, Yuan Tan, Qianqian Duan, Mei He
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients
Chao Li, Mengdong Zhang, Jianwen Wang, Xiaodong Zhang